Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Hazel Jones as Chief Operating Officer. Following a £10 million Series A financing in October 2022, Hazel’s appointment is the next step in the Company’s drive to broaden the application of its technology and secure strategic collaboration agreements with pharmaceutical partners. Hazel’s new role involves leading, scaling, and growing the Company’s global business operations. She will play an instrumental part in delivering the Company’s strategy to commercial and academic partners. Her responsibilities also include long-term strategic planning of logistics and managing alliances with stakeholders. Hazel has over 10 years of senior leadership experience in oncology research. She has significant expertise in working across functions to develop effective partnerships aligned with complex operational procedures. This delivers clear business objectives and maximizes the outcome of partnerships to advance disease ...
After this summer’s FDA approval of Iveric Bio’s Izervay—the drug at the center of the $5.9 billion buyout by Japanese pharma Astellas—the battle for the geographic atrophy (GA) crown is on in the U.S. Now, Apellis Pharmaceuticals, which boasts embedded eye disease sales leader Syfovre, is putting up long-term data in a bid to outdo its new rival. Touting data from its GALE extension study, Apellis on Saturday said Syfovre yielded increasing treatment effects year over year and helped patients achieve more than a 40% reduction in non-subfoveal lesion growth at the study’s three-year mark. Apellis rolled out the latest GALE results as part of a presentation at this year’s meeting of the American Academy of Ophthalmology (AAO) in San Francisco. The timing coincides with the release of two-year data on Astellas and Iveric’s GA drug Izervay—also at AAO—which suggest the rival drug’s treatment benefit emerged in as few as ...
Candel Therapeutics has announced positive results from a mid-stage trial of its viral immunotherapy candidate in non-metastatic pancreatic cancer. The ongoing phase 2 trial has been evaluating the candidate CAN-2409 plus valacyclovir together with standard of care (SoC) chemo-radiation followed by resection in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC). Interim results demonstrated an estimated survival rate of 71.4% at months 24 and 36 months in patients who received the CAN-2409 regimen prior to surgery, compared to 16.7% in those receiving SoC chemo-radiation alone. Five out of seven patients who received CAN-2409 were still alive at the time of the data cut-off, with two patients surviving more than 45 months from enrolment, while only one patient randomised to control SoC chemotherapy remained alive at the data cut-off. A “consistent and robust activation of immune response” was also observed after dosing with CAN-2409, the company said, and that the candidate ...
Amidst the rapidly growing revenue share of metabolic disease drugs in its pipeline, Eli Lilly is looking to delve deeper into its pharmaceutical exploration of obesity therapeutics, said medical director Axel Haupt. Haupt was speaking at a panel at the ongoing Bio-Europe 2023 conference, where he said drugs like Lilly’s Mounjaro (tirzepatide) carry potential to be used in for several conditions. The US Food and Drug Administration approved Eli Lilly’s Mounjaro for diabetes in May 2022, followed by the European Union in September 2022. The drug is administered via injection in a once-weekly regimen. Haupt revealed that an FDA approval for Mounjaro for treating obesity could be expected within the next 12 months. Obesity and diabetes treatment would likely not be the only use for Mounjaro, given the presence of GIP receptors in other locations like the adipose tissue, Haupt said. Eli Lilly sees potential use for the drug in ...
NRx Pharmaceuticals and Nephron Pharmaceuticals have come together in a bid to develop the first FDA-approved intravenous ketamine treatment for suicidal depression. The partnership will see NRx developing the drug while giving Nephron the responsibility of manufacturing the product. As per chief scientist and director Dr. Jonathan Javitt, NRx aims to deliver a two-year shelf-stable ketamine formulation to patients by November 2024. Nephron is in the process of setting the stage for submitting an New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the drug. The target deadline for filing the application is 1 March, 2024, said Nephron CEO Lou Kennedy. According to the US Centers for Disease Control and Prevention (CDC), suicide rates have risen by approximately 36% from 2000-2021, with suicide being the second leading cause of death in 2021 for individuals in the age groups of 10 –14 years and 20 –34 years. ...
BY SEAN WHOOLEY Align Technology (Nasdaq:ALGN) announced today that it plans to repurchase $100 million of its own common stock. Tempe, Arizona-based Align Technology’s open market repurchase falls under its $1 billion stock repurchase program. The company’s board approved the program in January 2023. Align Technology executed a $250 million repurchase in February of this year with Citibank. Last month, the company triggered another $250 million repurchase in an accelerated program. As with other repurchase efforts, Align Technology President and CEO Joe Hogan intends to personally purchase $1 million in common stock. He did the same in the company’s accelerated program last month. The company expects to complete the repurchases by mid-December 2023, funding them with cash on hand. As of Sept. 30, 2023, it had approximately 76.6 million shares outstanding with $1.3 billion in cash on hand. “Invisalign is the most trusted brand in the Orthodontic industry globally and ...
Discussions around healthcare’s workforce crisis usually center around providers’ lack of clinicians, but there’s a sweeping shortage of revenue cycle workers, too. In a new report, Experian Health surveyed 200 employees who are responsible for staffing the revenue cycle function at providers — every respondent said that staff shortages are having a significant negative impact on their organization’s ability to get paid for care and/or patient engagement. By KATIE ADAMS Healthcare’s workforce shortage is one of the most pressing — perhaps the most pressing — issue plaguing the industry. Discussions around this topic usually center around providers’ lack of physicians and nurses, but there’s a sweeping shortage of front and back office staff members, too. Experian Health, a company that sells revenue cycle management and patient engagement technology to providers, released a report last week shining light on this issue. To understand more about the healthcare sector’s workforce shortage among ...
Drugdu.com expert’s response: As a medical trade professional, effectively operating a B2B platform account is key to achieving good promotional results. Here are some suggestions to help you better manage and promote your B2B account: 1.Complete and professional company profile: Ensure your company profile (including company introduction, contact details, licenses, qualifications, etc.) is complete and up-to-date. High-quality images and clear product descriptions will enhance the appeal of your company and products. 2.Continuous product updates: Regularly update your product catalog, ensuring each product description is accurate and detailed. Provide key information such as product images, specifications, prices, and MOQ (Minimum Order Quantity). 3.Timely responses: For B2B buyers, a quick and professional response is crucial. Ensure you or your team can reply to buyer inquiries promptly. 4.Customer reviews and feedback: Encourage satisfied customers to provide positive feedback, which can increase trust from other potential buyers. For any negative feedback, respond promptly and attempt ...
Dive Brief The Food and Drug Administration will continue to allow medical device manufacturers to make alterations to certain products or manufacturing processes without prior authorization if the changes are due to production limitations or supply chain challenges. The policy is a continuation of COVID-19 pandemic-era changes that eased some requirements on device makers during the crisis. The guidance document, issued Thursday, outlines examples of when companies would not be required to file a premarket application (PMA) or humanitarian device exemption (HDE) supplement, or a 30-day notice, before making changes. While the policy was initially created for the emergency pandemic environment, the FDA wrote in the guidance document that it has “continued to observe supply chain challenges and shortages of medical devices remain widespread.” The agency removed the policy’s expiration date, but it could make revisions in the future. Dive Insight The guidance, first issued in May 2020, was supposed ...
Sharks differ from other fish in many ways, including an apparently remarkable ability to heal from wounds, according to reports of sharks recovering from injuries sustained in the wild. While this healing ability has not yet been documented in controlled laboratory conditions, some of the chemical compounds found in shark skin may have significant biomedical potential. To investigate this possibility, two dermatology researchers from the Karolinska Institute in Sweden carried out research on a small shark, the spiny dogfish (Squalus acanthias) and other cartilaginous fish species at the Marine Biological Laboratory (MBL) in Woods Hole. Their goal is to understand the unique biochemistry of the skin of these animals. Previous research on sharks in other labs has led to the development of a new antibiotic, and the discovery of biochemical pathways relevant to cystic fibrosis research. Jakob Wikström, associate professor of dermatology and principal investigator at Karolinska, and Etty Bachar-Wikström, ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.